| Recognize the core clinical features of dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), and differentiate them from Alzheimer’s disease and other atypical dementias. |
|
|
|
|
|
|
| Apply current diagnostic criteria and supportive biomarkers (DaT-SPECT, MIBG, PSG-confirmed RBD, and emerging α-synuclein seed amplification assays) in routine practice. |
|
|
|
|
|
|
| Implement evidence-based treatment strategies for cognition, neuropsychiatric symptoms (hallucinations, fluctuations), parkinsonism, sleep, and autonomic dysfunction. |
|
|
|
|
|
|